Literature DB >> 26740733

Cytoplasmic Maspin Expression Correlates with Poor Prognosis of Patients with Adenocarcinoma of the Uterine Cervix.

Kanae Nosaka1, Yasushi Horie1, Tatsushi Shiomi2, Hiroaki Itamochi3, Tetsuro Oishi4, Muneaki Shimada4, Shinya Sato4, Tomohiko Sakabe1, Tasuku Harada4, Yoshihisa Umekita1.   

Abstract

BACKGROUND: Maspin is known to be a tumor suppressor protein and its prognostic significance in patients with several types of cancer has been reported. To date, however, no study has focused on the association between maspin expression and the prognosis of patients with adenocarcinoma of the uterine cervix. We explored the prognostic value of maspin expression with particular reference to its subcellular localization in patients with adenocarcinoma of the uterine cervix.
METHODS: Paraffin-embedded tissue samples from 46 patients diagnosed as adenocarcinoma of the uterine cervix were immunohistochemically analyzed using an antibody for maspin. The patients were followed up for 3 to 165 months (median: 64.2 months) and the prognostic value was evaluated by the log-rank test and the Cox regression hazard model.
RESULTS: A sample was considered maspin-positive if maspin was expressed in only the cytoplasm; 69.6% (32 cases) of the specimens were maspin-positive, and there was significant correlation between positivity and recurrence (P = 0.022). Maspin-positive patients had both shorter disease free survival and shorter overall survival by the log-rank test (P = 0.023, P = 0.043, respectively). By Cox's multivariate analysis, the International Federation of Obstetrics and Gynecology (FIGO) status was the only independent prognostic factor for disease free survival and overall survival in patients with adenocarcinoma of the uterine cervix.
CONCLUSION: This is the first report to reveal an association between cytoplasmic maspin expression and the prognosis of patients with adenocarcinoma of the uterine cervix. Although further studies with a larger series of patients and a longer follow up period are necessary, the present results suggest that cytoplasmic maspin expression could be an indicator of unfavorable prognosis in patients with adenocarcinoma of the uterine cervix.

Entities:  

Keywords:  adenocarcinoma; immunohistochemistry; maspin; uterine cervix

Year:  2015        PMID: 26740733      PMCID: PMC4701986     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  23 in total

Review 1.  Adenocarcinoma: a unique cervical cancer.

Authors:  Lilian T Gien; Marie-Claude Beauchemin; Gillian Thomas
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

Review 2.  Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.

Authors:  Maria Lina Tornesello; Luigi Buonaguro; Franco M Buonaguro
Journal:  Gynecol Oncol       Date:  2012-11-17       Impact factor: 5.482

3.  Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis.

Authors:  Brigitte Goulet; Wendy Kennette; Amber Ablack; Carl O Postenka; M Nicole Hague; Joe S Mymryk; Alan B Tuck; Vincent Giguère; Ann F Chambers; John D Lewis
Journal:  Lab Invest       Date:  2011-04-18       Impact factor: 5.662

4.  Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.

Authors:  T Irie; J Kigawa; Y Minagawa; H Itamochi; S Sato; R Akeshima; N Terakawa
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

5.  Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring <3 cm.

Authors:  Yuzo Takagi; Yuki Matsuoka; Tatsushi Shiomi; Kanae Nosaka; Chikako Takeda; Tomohiro Haruki; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura; Yoshihisa Umekita
Journal:  Histopathology       Date:  2014-12-22       Impact factor: 5.087

6.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

7.  Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases.

Authors:  P J Eifel; M Morris; M J Oswald; J T Wharton; L Delclos
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

8.  Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.

Authors:  Y Umekita; H Yoshida
Journal:  Histopathology       Date:  2003-06       Impact factor: 5.087

9.  Cytoplasmic maspin expression predicts poor prognosis of patients with soft tissue sarcomas.

Authors:  Chikako Takeda; Yuzo Takagi; Tatsushi Shiomi; Kanae Nosaka; Hideki Yamashita; Mari Osaki; Koji Endo; Takeshi Minamizaki; Ryota Teshima; Hideki Nagashima; Yoshihisa Umekita
Journal:  Diagn Pathol       Date:  2014-10-30       Impact factor: 2.644

10.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
View more
  3 in total

1.  PI3K-AKT, JAK2-STAT3 pathways and cell-cell contact regulate maspin subcellular localization.

Authors:  M T Longhi; L E Silva; M Pereira; M Magalhães; J Reina; F N L Vitorino; B M Gumbiner; J P C da Cunha; N Cella
Journal:  Cell Commun Signal       Date:  2021-08-14       Impact factor: 7.525

2.  Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non-Smad signaling pathways.

Authors:  Ariyaphong Wongnoppavich; Nahathai Dukaew; Sirinthip Choonate; Kongthawat Chairatvit
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

3.  Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma.

Authors:  Min Wang; Bo Yuan; Zhen-Huan Zhou; Wei-Wei Han
Journal:  Sci Rep       Date:  2021-04-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.